1,092 results

#198511-AAV5

Ready-to-use AAV5 particles produced from pAAV_hSyn-DIO-PdCO-mScarlet-WPRE (#198511). In addition to the viral particles, you will also receive purified pAAV_hSyn-DIO-PdCO-mScarlet-WPRE plasmid DNA. Syn-driven Cre-dependent expression of optimized PdCO in frame with mScarlet. These AAV preparations are suitable purity for injection into animals.

Ofer Yizhar

Wietek et al Nat Methods. 2024 May 29. doi: 10.1038/s

Sept. 27, 2024

Academic Institutions and Nonprofits only

#213830-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiCHATe27_ChR2_mCherry (#213830). In addition to the viral particles, you will also receive purified pAAV_BiCHATe27_ChR2_mCherry plasmid DNA. Expression of mCherry-tagged channelrhodopsin-2 under the control of the cholinergic neuron-targeting enhancer E27. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#214862-PHPeB

Ready-to-use AAV PHP.eB particles produced from AiP14825: pAAV-AiE0441h_3xC2-minBG-iCre(R297T)-BGHpA (Alias: CN4825) (#214862). In addition to the viral particles, you will also receive purified AiP14825: pAAV-AiE0441h_3xC2-minBG-iCre(R297T)-BGHpA (Alias: CN4825) plasmid DNA. minBG-driven expression of iCre(R297T) in striatal medium spiny neurons. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Allen Institute for Brain Science, Jonathan Ting

Hunker et al Neuron. 2025 May 21;113(10):1507-1524.e1

Nov. 13, 2024

Academic Institutions and Nonprofits only

#45185-AAV9

Ready-to-use AAV9 particles produced from AAV-EF1a-BbTagBY (#45185). In addition to the viral particles, you will also receive purified AAV-EF1a-BbTagBY plasmid DNA. Brainbow construct encoding farnesylated TagBFP and EYFP, both in reverse orientation between mutant Lox sites. These AAV preparations are suitable purity for injection into animals.

Dawen Cai, Joshua Sanes

Cai et al Nat Methods. 2013 May 5;10(6):540-7. doi

March 7, 2018

Academic Institutions and Nonprofits only

#26969-AAV2

Ready-to-use AAV2 particles produced from pAAV-CaMKIIa-hChR2(H134R)-EYFP (#26969). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-hChR2(H134R)-EYFP plasmid DNA. CaMKIIa-driven, humanized channelrhodopsin H134R mutant fused to EYFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Lee et al Nature. 2010 Jun 10. 465(7299):788-92.

Feb. 14, 2018

Academic Institutions and Nonprofits only

#34910-AAV5

Ready-to-use AAV5 particles produced from paavCAG-pre-mGRASP-mCerulean (#34910). In addition to the viral particles, you will also receive purified paavCAG-pre-mGRASP-mCerulean plasmid DNA. CAG-driven expression of presynaptic mGRASP-mCerulean for synaptic connectivity mapping. These AAV preparations are suitable purity for injection into animals.

Jinhyun Kim

Kim et al Nat Methods. 2011 Dec 4;9(1):96-102. doi

Aug. 7, 2025

Academic Institutions and Nonprofits only

#83895-AAV9

Ready-to-use AAV9 particles produced from pAAV-hDlx-Flex-GFP-Fishell_6 (#83895). In addition to the viral particles, you will also receive purified pAAV-hDlx-Flex-GFP-Fishell_6 plasmid DNA. hDlx-driven, Cre-dependent expression of GFP. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Dimidschstein et al Nat Neurosci. 2016 Oct 31. doi: 10.1038/

Nov. 2, 2020

Academic Institutions and Nonprofits only

#213936-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV_BiPVe4_dTomato_nlsdTomato (#213936). In addition to the viral particles, you will also receive purified pAAV_BiPVe4_dTomato_nlsdTomato plasmid DNA. Bicistronic expression of dTomato and nuclear-targeted dTomato under the control of the chandelier cell-targeting enhancer E4. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Dec. 2, 2024

Academic Institutions and Nonprofits only

#35505-AAV9

Ready-to-use AAV9 particles produced from pAAV-CaMKIIa-hChR2(E123A)-EYFP (#35505). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-hChR2(E123A)-EYFP plasmid DNA. CaMKIIa-driven hChR2(E123A)-EYFP expression for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Mattis et al Nat Methods. 2011 Dec 18;9(2):159-72. do

May 24, 2018

Academic Institutions and Nonprofits only

#104489-AAV1

Ready-to-use AAV1 particles produced from pGP-AAV-syn-jGCaMP7b-WPRE (#104489). In addition to the viral particles, you will also receive purified pGP-AAV-syn-jGCaMP7b-WPRE plasmid DNA. Syn-driven jGCaMP7b calcium sensor. jGCaMP7b exhibits the brightest resting fluorescence of the jGCaMP7 variants, and can be used for imaging of small neuronal processes. These AAV preparations are suitable purity for injection into animals.

Douglas Kim, GENIE Project

Dana et al Nat Methods. 2019 Jul;16(7):649-657. doi

June 7, 2018

Academic Institutions and Nonprofits only